Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

Japan's Ministry of Health, Labour and Welfare approved eptinezumab, an intravenous CGRP-targeted preventive treatment for migraine attacks in adults. The authorization expands access in Japan for a therapy already launched in more than 30 countries and was supported by Phase clinical-trial data. The approval is a positive product and regulatory milestone, though the article does not disclose revenue expectations, pricing, or launch timing.